Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Invivyd often means wading through hundreds of pages to locate one cash-runway table or a single trial update. If you have ever searched “Invivyd SEC filings explained simply” or wondered which variant data moved the share price, you know the challenge.
Stock Titan solves that problem. Our AI reads every Invivyd annual report 10-K simplified, parses each Invivyd quarterly earnings report 10-Q filing, and flags fresh Invivyd 8-K material events explained within minutes of hitting EDGAR. Interactive summaries highlight R&D spend, dilution risk, and regulatory milestones, while side-by-side charts let you compare pipeline disclosures over time.
Need real-time trade intel? Form 4 alerts surface Invivyd executive stock transactions Form 4, giving you immediate insight into insider sentiment. Our dashboard also groups every Invivyd proxy statement executive compensation section, so you can evaluate incentives driving decision-making.
- AI-powered summaries translate technical immunology terms into plain English
- Instant notifications for Invivyd Form 4 insider transactions real-time
- Side-by-side “redline” view of successive reports for quick change detection
Whether you type “Invivyd earnings report filing analysis,” “understanding Invivyd SEC documents with AI,” or “Invivyd insider trading Form 4 transactions,” this page delivers the answers—and the filings—without the usual time sink.
Invivyd, Inc. describes regulatory and clinical progress for its COVID-19 monoclonal antibody programs and terms of a securities offering. The company notes PEMGARDA (pemivibart) is authorized for pre-exposure prophylaxis in certain immunocompromised patients under emergency use with restrictions tied to national variant susceptibility thresholds. It reports VYD2311 completed positive Phase 1/2 safety and pharmacokinetic data and that the FDA advised a compact Phase 2/3 trial could support a BLA for prevention of COVID-19 in persons 12 years and older (>=40 kg), subject to agreement on safety database size and final protocol review. The prospectus supplement discloses intended use of proceeds to advance VYD2311 clinical development, other R&D (including RSV and measles), SPEAR Study Group work on Long COVID/PVS, and general corporate purposes. It also details offering mechanics: lock-up provisions (60 days), at-the-market sales ($39.3 million sold to date, $34.5 million available), registration rights, and various U.S. and non-U.S. tax and resale considerations.
Timothy Edward Lee, Chief Commercial Officer of Invivyd, Inc. (IVVD), reported equity activity arising from an RSU grant and subsequent sell-to-cover transactions executed under a Rule 10b5-1 plan.
On 08/15/2025 Mr. Lee was granted 99,000 RSUs (each converting to one share) that vest over 18 months with one-third vesting every six months. After accounting for the RSUs and existing holdings (including 10,000 shares from the company ESPP), the reported post-transaction beneficial ownership is 201,000 shares. To satisfy tax withholding upon RSU vesting, Mr. Lee sold 20,013 shares on 08/18/2025 at a weighted average price of $0.6502 and 29,643 shares on 08/19/2025 at a weighted average price of $0.5666. The sales were non-discretionary sell-to-cover transactions pursuant to a 10b5-1 plan adopted 02/20/2025.
Invivyd, Inc. (IVVD) Chief Financial Officer William E. Duke reported equity transactions tied to an RSU award granted Feb 15, 2025. The Form 4 shows 99,000 restricted stock units (RSUs) were granted (each convertible into one share) and vest over 18 months with one-third vesting every six months. On 08/15/2025 the Reporting Person was credited with 99,000 RSUs. Sell-to-cover transactions pursuant to a Rule 10b5-1 plan occurred on 08/18/2025 and 08/19/2025 to satisfy tax-withholding: 20,013 shares sold at a weighted average price of $0.6502 and 29,643 shares sold at a weighted average price of $0.5666. After these sales, the Reporting Person beneficially owned 78,987 shares and held 201,000 shares underlying outstanding RSUs and awards in total.
Julie Green, Chief Human Resources Officer of Invivyd, Inc. (IVVD), reported RSU vesting and sell-to-cover sales in mid-August 2025. The Form 4 shows the vesting of 99,000 restricted stock units on 08/15/2025 and subsequent nondiscretionary sales executed under a Rule 10b5-1 plan to satisfy tax-withholding: 20,013 shares sold on 08/18/2025 at a weighted average price of $0.6502 and 29,643 shares sold on 08/19/2025 at a weighted average price of $0.5666. After these transactions the report lists 49,344 shares beneficially owned directly following the 08/19/2025 sale. The filing discloses the 10b5-1 plan adoption date of February 20, 2025, and that the RSUs vest in three equal tranches over 18 months beginning February 15, 2025.
Jill Andersen, Chief Legal Officer and Secretary of Invivyd, Inc. (IVVD), reported equity activity on Form 4 related to restricted stock units and subsequent sell-to-cover sales. On 08/15/2025 she was credited with 165,000 RSUs (each converting to one common share) under an award that vests one-third every six months beginning from a 02/15/2025 grant date. Following vesting, she sold 33,352 shares on 08/18/2025 at a weighted average price of $0.6502 and 49,402 shares on 08/19/2025 at a weighted average price of $0.5666, in non-discretionary sell-to-cover transactions adopted under a Rule 10b5-1 plan. The Form shows 84,446 shares beneficially owned after the reported sales (direct), plus 500 shares indirectly held by spouse.
Robert D. Allen III, Chief Scientific Officer of Invivyd, Inc. (IVVD), reported RSU vesting and related sell-to-cover transactions. On 08/15/2025 he recorded the vesting of 99,000 restricted stock units, each converting to one share. To satisfy tax withholding, the reporting person sold 18,512 shares on 08/18/2025 at a weighted average price of $0.6502 and 27,420 shares on 08/19/2025 at a weighted average price of $0.5666. Following those transactions, he beneficially owns 53,068 shares directly and reports 201,000 shares beneficially owned in total after accounting for derivative holdings. The sales were made under a Rule 10b5-1 plan adopted on 02/20/2025 and were non-discretionary sell-to-cover transactions for tax purposes. The RSU award vests over 18 months with one-third vesting every six months beginning 02/15/2025.
Invivyd, Inc. filed a Form 144 announcing a proposed sale of 39,600 shares of its common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $28,001.16. The filing states the shares were acquired on 08/15/2025 upon vesting of restricted stock units granted under the company’s 2021 Equity Incentive Plan and that payment was classified as Equity Compensation. The filer indicates no sales of the issuer’s securities in the past three months. The approximate date of sale is listed as 08/18/2025 on Nasdaq. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Form 144 notice for Invivyd, Inc. (IVVD): An insider filed a proposed sale of 66,000 shares of Common Stock on Nasdaq with an aggregate market value of $46,668.60, approximately 0.055% of the reported 120,142,811 shares outstanding. The securities were acquired on 08/15/2025 when 165,000 shares vested as restricted stock units under the company's 2021 Equity Incentive Plan, and the sale was slated for 08/18/2025 through Morgan Stanley Smith Barney LLC Executive Financial Services. The filer certifies absence of undisclosed material adverse information and notes no securities sold in the past three months.
Invivyd, Inc. (IVVD) filed a Form 144 notifying a proposed sale of 36,631 shares of Common Stock on or about 08/18/2025 through Morgan Stanley Smith Barney LLC on Nasdaq, with an aggregate market value of $25,901.78. The securities were acquired on 08/15/2025 upon vesting of restricted stock units granted under the issuer's 2021 Equity Incentive Plan and payment was recorded as Equity Compensation. The filer reports “Nothing to Report” for securities sold during the past three months. Several identifying filer fields in the filing (CIK, contact name, phone, email, and issuer name/address) are not provided in the supplied content.
Invivyd, Inc. (IVVD) filed a Form 144 reporting a proposed sale of 39,600 shares of common stock on 08/18/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $28,001.16. The shares were acquired on 08/15/2025 upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan; 99,000 shares were acquired upon vesting and payment was by equity compensation on 08/15/2025. The filing shows 120,142,811 shares outstanding and indicates no reported sales by the seller in the past three months.
FAQ
What is the current stock price of Invivyd (IVVD)?
What is the market cap of Invivyd (IVVD)?
